Publications by authors named "Leyla R Tilova"
Int J Mol Sci
August 2024
Article Synopsis
- Glucocorticoids (GCs) are commonly used to treat blood cancers but can cause various side effects due to how they interact with glucocorticoid receptors (GRs).
- Selective GR agonists (SEGRAs) like CpdA aim to enhance the beneficial anticancer effects while minimizing side effects; however, CpdA faces challenges with chemical instability.
- The newly developed derivative, CpdA-03, shows improved stability and GR affinity, demonstrating significant anticancer activity in lymphoma models, with a tripling reduction in tumor volume compared to conventional treatments.
